Sound Income Strategies’s Seres Therapeutics MCRB Stock Holding History

Sound Income Strategies’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8	Closed	-$71	–	1604
2026 Q1	$71	Hold	8	–	–	﹤0.01%	2523
2025 Q4	$128	Hold	8	–	–	﹤0.01%	2448
2025 Q3	$156	Buy	+8	New	+$128	﹤0.01%	1613
2025 Q2	–	Sell	-9	Closed	-$123	–	1667
2025 Q1	$123	Hold	9	–	–	﹤0.01%	1491
2024 Q4	$145	Hold	9	–	–	﹤0.01%	1412
2024 Q3	$166	Hold	9	–	–	﹤0.01%	1355
2024 Q2	$127	Hold	9	–	–	﹤0.01%	1325
2024 Q1	$135	Hold	9	–	–	﹤0.01%	1294
2023 Q4	$245	Hold	9	–	–	﹤0.01%	1262
2023 Q3	$417	Hold	9	–	–	﹤0.01%	1082
2023 Q2	$838	Hold	9	–	–	﹤0.01%	995
2023 Q1	$992	Buy	+9	New	+$974	﹤0.01%	934

Other funds holding MCRB

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

RIAS

Rachor Investment Advisory Services Linden, Michigan $203M AUM

WTC

WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return

Sound Income Strategies's MCRB Position: Q2 2026 in Review

Sound Income Strategies sold out of Seres Therapeutics (MCRB) in Q2 2026, closing a stake of 8 shares — an estimated $71 sold.

Sound Income Strategies first reported a position in MCRB in Q1 2023 and held it in 12 quarters. The position peaked at $992 in Q1 2023. 4 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

Sound Income Strategies reported no remaining Seres Therapeutics position as of Q2 2026 after selling out during the quarter.
Sound Income Strategies sold 8 Seres Therapeutics shares in Q2 2026, an estimated $71.
Sound Income Strategies first reported a position in Seres Therapeutics in Q1 2023 and held it in 12 quarters.
Sound Income Strategies's Seres Therapeutics position peaked at $992 in Q1 2023.
4 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.